PDCD1 and cancer: Further investigation to establish causal relationship (if present) and the underlying mechanism between PD-1 inhibitor initiation and development of neuropathy may identify pharmaceutical targets for the prevention of immunotherapy-associated neuropathy and amplification of the efficacy of PD-1 inhibitors in the treatment of cancers.